Ketamine Troches and Suicidal Ideation

Ketamine Troches and Suicidal Ideation: What the Research Shows

Suicidal ideation means thoughts of wanting to die or of ending one's own life, ranging from passive wishes to a specific plan with intent. It is treated as a psychiatric emergency because the period of highest risk can be brief and hard to predict. Standard antidepressants take 4 to 8 weeks to reach full effect, which makes them poorly suited to an acute suicidal crisis. Electroconvulsive therapy (ECT) works faster but requires anesthesia and inpatient or specialized outpatient access.

Ketamine, an NMDA receptor antagonist that blocks a subtype of glutamate receptor involved in mood and pain signaling, was first approved by the FDA as an anesthetic in 1970. Research on ketamine troches and suicidal ideation has grown because clinical trials have measured reductions in suicidal thoughts within hours of administration, a timeline distinct from and faster than ketamine's antidepressant effect. This article reviews the clinical evidence, the mechanisms researchers have proposed, and the safety measures a responsible prescriber uses when treating a patient who has suicidal thoughts. For more on ketamine's effects over a full course of treatment, see our guide to treatment-resistant depression and ketamine troches.

The Antisuicidal Effect: What the Evidence Shows

Randomized Trials and the ASPIRE Program

Diazgranados et al. (2012) and later work from the National Institute of Mental Health found rapid reductions in suicidal ideation scores on the Hamilton Depression Rating Scale and the MADRS suicidality item within 24 hours of an IV ketamine infusion (0.5 mg/kg). The ASPIRE-1 and ASPIRE-2 trials, which supported the FDA's approval of esketamine (Spravato) for major depressive disorder with suicidal ideation, found that intranasal esketamine (56 mg or 84 mg, twice weekly for 4 weeks) significantly reduced MADRS suicidality subscale scores compared to placebo at 24 hours.

Grunebaum et al. (2017) compared ketamine directly to midazolam, an active placebo, in a randomized trial that used suicidal ideation itself, not depression, as the primary outcome. Ketamine produced a greater reduction in suicidal ideation at 24 hours, which helped establish an antisuicidal effect that does not depend entirely on general antidepressant response.

More recent research adds to this picture. A systematic review covering 16 clinical trials published between 2020 and 2024 found that multiple doses of IV ketamine or esketamine were associated with sustained reductions in suicidal ideation lasting days to weeks, while single doses and intranasal-only formulations produced less consistent results. A retrospective U.S. cohort study of more than 500,000 patients with recurrent major depressive disorder found that patients treated with ketamine had a lower likelihood of a suicidal ideation event, with hazard ratios ranging from roughly 0.63 in the first week to 0.78 over the following nine months compared to patients not treated with ketamine.

How Fast Does It Work?

The antisuicidal effect of IV ketamine is typically evident within 2 to 4 hours of infusion and peaks around 24 hours later. Some patients notice relief from suicidal thoughts during or immediately after the session. This window, measured in hours rather than weeks, matters clinically because the period of highest suicide risk can be short.

Is the Effect Independent of Antidepressant Effects?

Researchers have asked whether ketamine reduces suicidal ideation directly or only as a side effect of improving depression overall. The evidence suggests the two effects are at least partially separate: several studies have documented reductions in suicidal ideation in patients who showed little antidepressant response, and the time course of suicidal ideation reduction is generally faster than the time course of a full antidepressant response. The underlying mechanisms likely overlap but are not identical.

Proposed Mechanisms

AMPA Receptor Signaling and the HNK Metabolite

Research by Bhatt et al. and others points to AMPA receptor signaling, the same glutamate receptor pathway implicated in ketamine's rapid antidepressant effects, as part of the antisuicidal mechanism. Hydroxynorketamine (HNK), a metabolite the body produces as it breaks down ketamine, may contribute by modulating AMPA receptors without producing the dissociative effects associated with ketamine itself.

Suppression of Lateral Habenula Activity

Another proposed mechanism involves the lateral habenula, a small brain structure sometimes called the brain's antireward center because it becomes active during disappointment, failure, and negative expectation. The lateral habenula has a high density of NMDA receptors and extensive connections to reward and mood circuits. Researchers have proposed that ketamine's rapid antisuicidal effect may work partly by suppressing burst firing in this region, though the mechanism is still being studied and has not been fully confirmed in humans.

Reduction of Hopelessness

Hopelessness, the belief that one's situation cannot improve, is one of the strongest predictors of suicidal behavior. Ketamine appears to reduce this specific cognitive distortion more quickly than it improves other measures of depression, which may reflect direct effects on prefrontal circuits involved in future-oriented thinking.

Psychological Effects of the Session Experience

The altered state ketamine produces, including a temporary loosening of ego boundaries and a shift in perspective, may itself reduce the cognitive rigidity and tunnel vision common in acute suicidal crises. Patients sometimes describe the period after a session as a kind of reset that lets them see options that felt invisible during a suicidal crisis.

The Safety Paradox: Prescribing Ketamine to Patients With Suicidal Ideation

Prescribing any controlled substance to a patient with active suicidal ideation creates a real tension: the medication meant to help could theoretically be misused in an overdose attempt. This concern deserves to be taken seriously, and clinical context helps explain how prescribers manage it.

Ketamine's Overdose Profile

Unlike opioids, benzodiazepines, or acetaminophen, which are commonly involved in overdose attempts, ketamine has a wide therapeutic index. According to the StatPearls clinical reference on ketamine, overdose in otherwise healthy individuals is rarely fatal, with respiratory depression as the primary risk, and that risk requires doses well above what is prescribed in troche therapy. This does not make ketamine safe to misuse, but it does mean a troche prescription carries a lower overdose risk than many other medications a patient with depression and suicidal ideation may already have access to.

Structured Administration

At-home troche use may not be appropriate for a patient with significant active suicidal ideation. For patients in acute crisis, clinic-based administration provides the monitoring needed during the highest-risk window. As suicidal ideation comes under better control over the course of treatment, a transition to more autonomous at-home administration can follow, guided by the prescriber's clinical judgment. Our guide on working with your provider covers what this collaboration typically involves.

Clinical Application for Suicidal Ideation

FDA-Approved Esketamine (Spravato)

Esketamine (Spravato) is FDA-approved specifically for major depressive disorder with acute suicidal ideation or behavior, which makes it the regulatory-appropriate first option when this is the primary indication and the patient has access to a certified administration facility. See our comparison of intranasal esketamine and ketamine troches for how the two options differ in efficacy and access.

Compounded Ketamine Troches

Off-label use of compounded ketamine troches for suicidal ideation reduction is occurring in clinical practice. Providers who prescribe troches for this purpose should document the clinical rationale, address lethal means and safe storage directly in the prescription plan, dispense in small quantities per fill, use enhanced follow-up with more frequent check-ins and clear crisis protocols, and consider monitored clinic or office administration during the most acute phase of treatment. Our ketamine troche safety guide covers dosing, storage, and monitoring in more detail. For a closer look at research specific to treatment-resistant cases, see ketamine-resistant depression and suicidal ideation research.

Cost and Access Considerations

Cost and insurance coverage remain significant barriers to ketamine therapy generally. According to STAT News reporting on ketamine access, IV ketamine sessions often cost $400 to $1,000 out of pocket, and insurance reimbursement is frequently minimal or absent, which can force patients to weigh treatment against other financial needs. Troche therapy, administered sublingually rather than by infusion, typically involves a different cost structure. See our guides on what ketamine troches cost and the insurance coverage gap and patient assistance options for details relevant to troche therapy specifically.

Further Reading

• StatPearls: Ketamine, a clinical reference on ketamine pharmacology and mechanisms of action
• PubChem: Ketamine Compound Summary, the NCBI chemical database entry with molecular and pharmacokinetic data
• NIMH: Depression, the National Institute of Mental Health overview of depressive disorders and emerging treatments
• WHO: Depression Fact Sheet, global data on depression prevalence and treatment approaches
• 988 Suicide & Crisis Lifeline, free and confidential crisis support available 24/7